DOCSLIB.ORG

View a High-Resolution PDF Version of the Magazine Here

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
View a High-Resolution PDF Version of the Magazine Here CELEBRATING 5+ YEARS OF KNOWLEDGE TRANSLATION BUSTING BLOOD CLOTS MAY 2021 PREDICTING SARS-COV-2 EVOLUTION CHALLENGING THE DOGMA OF INNATE LYMPHOID CELL DEVELOPMENT D ABOUT CBR TABLE OF CONTENTS PUBLISHED BY Knowledge Translation Committee 4 Notes from the Director DESIGNER The CBR aims to improve the health and well-being Kristine Ho of patients through innovative research in blood and CONTRIBUTING EDITORS Dr. Amy Glenwright* RESEARCH OPINION blood-related processes. Amy Wong Strilchuk* Andy An* Nobel Prize: Who Lives, Aparna Gopal* “Going Viral” Video Series Who Dies, Who Tells Bronwyn Lyons 6 22 Cecilia Haymin Kim Your Story Fennie Easton van der Graaf Dr. Geraldine Walsh* Guillermo Caballero Silva Predicting the Evolution Dr. Kelly McNagny Science Communication GOALS Kristine Ho* 9 of SARS-CoV-2 Proteins Maria-Elizabeth Baeva 25 During the Pandemic CBR Research & Clinical Goals Marie-Soleil Smith* Melina Messing Challenging Innate • Improve the quality and safety of Dr. Michael Hughes* Stem Cell Therapy: blood product collection, storage and Nancy Yang* 10 Lymphoid Cell Dogma Polina Petlitsyna 26 Unapproved Treatments delivery Sarah Bowers* Dr. Yanina-Yasmin Pesch* • Create new knowledge to better treat Busting Deadly Blood * indicates Editorial Board member Nobel Prize: Between bleeding and clotting disorders Clots 12 Acknowledgement and • Develop novel approaches to COVER ART National Cancer Institute, 30 modulate the immune system to “Vaccine-Based Immunotherapy from Novel Atonement Patient-driven. Innovative. Community. Nanoparticle Systems” treat inflammation and infections and BLOG cbr.ubc.ca Just Keep Swarming Over the past year, donor support has helped us develop novel approaches FACEBOOK @cbrubc 14 promote wound repair TWITTER @CBR_UBC Stem Cell Therapy: to battle severe bleeding in rural areas, delineate the mechanisms of inflam- INSTAGRAM @cbr_ubc 32 Strengthening Regulations matory diseases, and increase the quality of blood products used in trans- The CBR magazine is published by the fusions — only a few examples among many pioneering discoveries. With Knowledge Translation (KT) Committee, AWARDS a group of undergraduates, graduate your continued support, the CBR will further transform innovative ideas into students, postdoctoral fellows, research Dr. Kizhakkedathu SPECIAL FEATURES life-enhancing solutions. associates, and technicians who are interested in science writing, blogging, 11 Inducted as FBSE and mixed media communications. It Dr. Dana Devine is distributed free of charge to CBR and 5 Appointed CBR Director The CBR needs you to help fund our programs, which range from $50 to UBC alumni, friends, and the scientific $100,000. We invite you to explore opportunities at the CBR where your community. Opinions expressed in the UBC Science Co-op magazine do not necessarily reflect the partnership with us will result in positive impacts on education, training and views of the centre or the university. 23 Supervisor Awards Lost in Lab: Deciphering meaningful research. Examples of initiatives that need your support include: Address correspondence to: 15 Blood Immune Cells The Centre for Blood Research 4th Floor, Life Sciences Centre Dr. Cheung Elected as Opportunity Cost 2350 Health Sciences Mall 29 AIMBE Fellow Vancouver, BC, Canada V6T 1Z3 Celebrating 5+ Years of Reward leadership in students and staff with the Neil $50 24 Knowledge Translation Mackenzie Mentorship Award The KT Committee publishes weekly at CBR News (cbr.ubc.ca) and covers a CBR Travel Awards Expose trainees to diverse career opportunities with the $1,000 wide range of topics, from recent research highlights and opinion pieces on science 33 2020-2021 CBR Career Night Cell Biology Lessons for and academia, to event coverage and Jumpstart a postdoctoral fellow’s career with the $5,000 CBR initiatives. If you are interested in 28 Seniors EDUCATION participating in the KT Committee, email Postdoctoral Transition Award Kristine at: [email protected] or talk to PROFILES CBR Education Commitment one of the members! All undergraduates, Support a clinical fellow in Translational Research Studies $75,000 • Support student research through graduate students, PDFs, RAs, and technicians are welcome to join. EVENTS Make a CBR Symposium possible $25,000- competitive undergraduate, graduate, Dr. Peter Schubert $100,000 and postgraduate awards CONTACT 16 Earl Davie Symposium [email protected] Explore further: CBR.ubc.ca/support-us • Offer a range of stimulating educational 18 2020 Dana Devine, MA, PhD symposia, workshops, and seminars CBR #WomenInScience Director, Centre for Blood Research • Provide cutting-edge career 34 Profiles Norman Bethune Tel: 604.822.7270 | Email: [email protected] development opportunities for our Knowledge 20 Symposium 2020 trainees Translation Committee Science beyond academia 3 The CBR welcomes Dr. Dana Devine as Director Notes from Devine’s Chair — BY KRISTINE HO, COMMUNICATIONS COORDINATOR, May 2021 CBR ADMIN TEAM s of January 1st, 2021, the Centre for Blood She pointed out that the CBR, which initially had many Research (CBR) was pleased to welcome Dr. Dana basic scientists as members, has since then strengthened its Devine as Director. She succeeds Dr. Ed Conway, clinical and industry connections. It has also expanded to include pring has finally arrived in Vancouver! But still an unusual A the CBR’s previous Director of 11 years. faculty and trainees from a wide variety of fields like engineering, S spring, as we see COVID-19 cases at over 800 per day in biochemistry, dentistry, molecular biology and the social British Columbia and further restraint on movement throughout “I’m honoured to accept the position of Director, and look sciences, among many others. the province. Now that anyone over the age of 18 can register forward to building on the CBR’s successes,” said Dr. Devine. In for a vaccination in BC, we are hopefully about to turn a corner addition to her long-time work with the CBR, Dr. Devine holds “The successes of the CBR have been built on many, many toward more normal life for everybody, including our Centre for many other reputable positions, including her roles as a professor shoulders,” added Dr. Conway. “I think that’s where the value is: in Blood Research (CBR) community. For over a year now, we’ve had in UBC’s Department of Pathology and Laboratory Medicine, the everybody’s contributions.” a virtual world of seminars and symposia, transitioned to remote or chief scientist at the Canadian Blood Services, the president- socially-distanced work, and seen some rather unusual remote experiences for our summer elect of the American Association of Blood Banks (AABB), and Building on the CBR’s growth, Dr. Devine plans to focus students in 2020. Though there have undoubtedly been many changes in our lives, from the Editor-in-Chief of the blood transfusion journal Vox Sanguinis. on several key areas during her four-year term. These include the added stress of working from home to the additional considerations associated with continuing to strengthen connections with other departments COVID-19 safety precautions in labs, I know that we have taken great strides to meet the As one of the CBR’s founding members, Dr. Devine has been and prospective collaborators, translating discoveries into challenges that these times have presented to us. A sincere thank you to CBR members for an integral part of the Centre since the beginning. She helped write applied use for patient benefit, establishing a faculty renewal your continued efforts in keeping each other safe. Hopefully, UBC campus will look a little the $15 million Canadian Foundation for Innovation (CFI) grant strategy aligned with equity, diversity and inclusion initiatives, more normal in September. application that led to the CBR’s creation following the Krever inquiry, and improving fundraising and support for the Centre. along with other founding members Drs. Ross MacGillivray, Grant We have continued to see many of our labs rapidly step up to work on COVID-19 Mauk, Don Brooks, and Charles Haynes. With strong connections to “Dana’s a superstar,” said Dr. Conway. “She’ll be a fantastic questions, setting aside what they might have otherwise been researching. Indeed, there other UBC departments, as well as the Canadian Blood Services, Dr. person to advance our existing foundations and lead the CBR in new has never been a topic so widely and quickly studied by so many scientists, sparking Devine also initiated essential partnerships with collaborators across directions, for research, educational programming and beyond.” collaborations across the globe. This is science at its best: people joining forces and the divide of different organizations and academic disciplines. The working together to help society in a time of great need. From optimizing COVID-19 tests, result was the establishment of the CBR in 2002, a multidisciplinary “Dr. Devine has a wealth of knowledge in strategic planning to investigating the mechanisms through which the virus functions, to investigating how research institute that was unlike any other. and transfusion medicine, as well as developing applied blood the virus affects the blood, body and more — I commend you all on your important roles products at the national and international level,” said Dr. Josef in this work. “If you go back 20 years, there was no such thing as a truly Penninger, the Director of the Life Sciences Institute (LSI) at UBC, multidisciplinary, multi-faculty blood research centre,” said Dr. of which the
Load more

Recommended publications
  • Transfusion Service, Massachusetts General Hospital, Harvard Medical School, Boston Editor, Transfusion Medicine Reviews Financial Disclosure
    The Present and Future of Medical Publication Sunny Dzik, MD Blood Transfusion Service, Massachusetts General Hospital, Harvard Medical School, Boston Editor, Transfusion Medicine Reviews Financial Disclosure: Stipend from Elsevier Publishing for my role as Editor of Transfusion Medicine Reviews. I have no other conflicts of interest to declare. For 20 centuries In the 15th Century Moveable type ! 1450 Source: wikipedia Henry Oldenburg 1st Scientific Editor Introduced the idea of scientific peer review Source: insights.uksg.org For 20 centuries In the 15th Century Now 1450 The Internet is changing all aspects of medical publication 1. Business model for publishers. 2. Metrics to ”rank” scientific publication. 3. Opportunity for fraud, plagiarism & the ability to catch it. 4. Dimensions of information transfer. 5. Sheer volume of information and importance of quality. 1. Business Models for Medical Publication Individual subscription model becoming extinct. Publishers sell a ‘bundle’ of journal titles to libraries. Users access individual articles on line. Packaging articles in “volumes” with “page numbers” may seem increasingly out-of-date.* *DOI = digital object identifier How Medical Libraries Used to Store Articles Medical College Library in Tanzania kcmuco.ac.tz/home/ ‘Open Access’ publishing . Article is made freely available to all online immediately after acceptance. Author, Institution, or Grant Funds pay an ‘article publication fee’. Some journals publish exclusively open access (PLOS, Biomed Central). Most journals are mix of subscription and open access options. Open access can offset subscription costs. Devised at the University of Leiden Vox Sanguinis: Open access $3300 Free self-archive access after 12 months Transfusion: Open access $3900 Free self-archive access after 12 months Transfusion Medicine Reviews: Open access $2500 Free self-archive access after 12 months Globally: Funders Embrace Open Access (but usually do not pay for it) Image courtesy of Elsevier 2.
    [Show full text]
  • Annual Report 2020 2021 Table of Contents
    ANNUAL REPORT 2020 2021 TABLE OF CONTENTS • Mission, vision and goals 3 • Platelet Immunobiology Working Party 26 • Foreword from the President 4 • Quality Management Working Party 27 • Foreword from the Secretary General 6 • Rare Donor Working Party 29 • Board of Directors 7 • Red Cell Immunogenetics and Blood Group Terminology 30 • Membership 2020-2021 8 Working Party • Report from the Young Professionals Council 9 • Transfusion Transmitted Diseases Working Party 32 • Financial Summary 10 • Reports from ISBT Standing Committees 35 • Congresses 11 • ISBT Standing Committee of the ISBT Academy 36 • Reports from ISBT Working Parties 12 • ISBT Standing Committee on Ethics 39 • Blood Supply Management Working Party 13 • ISBT Standing Committee on Jean Julliard Prize 40 • Cellular Therapy Working Party 15 • ISBT Standing Committee of Vox Sanguinis 42 • Clinical Transfusion Working Party 16 • Report from Vox Sanguinis 43 • Donors and Donation Working Party 18 • Report from the ISBT Science Series 45 • Global Blood Safety Working Party 19 • Report from ISBT Foundation 47 • Granulocyte Immunobiology Working Party 21 • ISBT Award and Prizes 48 • Haemovigilance Working Party 22 • Immunohaematology Working Party 24 • Information Technology Working Party 25 Corporate Partners ISBT is pleased to acknowledge the following Corporate Partners during 2020-2021 2 2020-2021 Annual Report MISSION, VISION AND GOALS The International Society of Blood Transfusion (ISBT) is a scientific society that was founded in 1935. Since that time the ISBT has grown in to an international society where transfusion medicine professionals from across the globe come together and do the one thing they do best: share knowledge to improve the safety of blood transfusion worldwide.
    [Show full text]
  • Which Is the Preferred Blood Product for Fibrinogen Replacement in The
    SUPPLEMENT ARTICLE Which is the preferred blood product for fibrinogen replacement in the bleeding patient with acquired hypofibrinogenemia— cryoprecipitate or fibrinogen concentrate? Melissa M. Cushing ,1 Thorsten Haas,2 Keyvan Karkouti,3,4 and Jeannie Callum5,6,7 PRO FIBRINOGEN CONCENTRATE: The importance of the targeted treatment of acquired FIBRINOGEN CONCENTRATE IS THE hypofibrinogenemia during hemorrhage with a PREFERRED BLOOD PRODUCT FOR concentrated fibrinogen product (either cryoprecipitate or FIBRINOGEN REPLACEMENT IN THE fibrinogen concentrate) cannot be underestimated. BLEEDING PATIENT WITH ACQUIRED Fibrinogen concentrate is a pathogen inactivated, pooled HYPOFIBRINOGENEMIA product that offers a highly purified single factor concentrate. Cryoprecipitate is a pooled product that hrough this section of our debate, we will attempt comes with a spectrum of other coagulation factors to convince you to abandon cryoprecipitate (if you which may further enhance (additional procoagulant have not already done so) for the management of effect) or even disturb (prothrombotic risk) hemostasis. hemorrhage in the presence of acquired hypo- Tfibrinogenemia (fibrinogen level less than 1.5-2.0 g/L). It is The pros and cons of each product are discussed. crucial for the safety of future generations of transfusion recip- ients that all blood products transfused are pathogen inactivated (where available, safe, and effective).1 Although there are numerous hurdles to the implementation of pathogen-inactivation technologies across all manufactured blood products
    [Show full text]
  • 19 Respiratory Illness (CONCOR-1): Study Protocol for an International, Multicenter, Randomized, Open- Label Trial
    Convalescent plasma for adults with acute COVID- 19 respiratory illness (CONCOR-1): Study protocol for an international, multicenter, randomized, open- label trial Philippe Bégin Université de Montréal: Universite de Montreal Jeannie Callum University of Toronto Nancy Heddle McMaster University Richard Cook University of Waterloo Michelle P Zeller McMaster University Alan Tinmouth University of Ottawa Dean Fergusson Ottawa Hospital Research Institute Melissa M Cushing Weill Cornell Medicine Marshall J Glesby Weill Cornell Medical College: Weill Cornell Medicine Michaël Chassé Université de Montréal Dana V Devine Canadian Blood Services Nancy Robitaille Héma-Québec Renée Bazin Héma-Québec Nadine Shehata University of Toronto Andrés Finzi Université de Montréal Page 1/34 Allison McGeer University of Toronto Damon Scales University of Toronto Lisa Schwartz McMaster University Alexis F Turgeon Universit Laval Ryan Zarychanski University of Manitoba Nick Daneman University of Toronto Richard Carl n/a Luiz Amorim Hemorio Caroline Gabe McMaster University Martin Ellis Tel Aviv University Erin Jamula McMaster University Julie Carruthers McMaster University Joanne Duncan McMaster University Kayla Lucier McMaster University Chantal Armali Sunnybrook Health Sciences Centre Amie Kron Sunnybrook Health Sciences Centre Dimpy Modi Sunnybrook Health Sciences Centre Marie-Christine Auclair Centre de recherche du CHU Sainte-Justine Meda Avram Centre de recherche du CHU Sainte-Justine Donald M Arnold ( [email protected] ) Page 2/34 McMaster University https://orcid.org/0000-0003-0943-8853 Research Article Keywords: convalescent plasma, SARS-CoV-2, coronavirus, COVID-19 Posted Date: March 5th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-268937/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License.
    [Show full text]
  • Featured Article Columbia Researchers United Against COVID-19
    Summer/Fall COLUMBIA PATHOLOGY 2020 AND CELL BIOLOGY REPORT Featured Article Columbia Researchers United Against COVID-19 Lab Snapshot Effects of COVID-19 on Histology Lab COVID-19 Response Departmental collection of the clinical response to the pandemic in this issue 3 From the Chair 4 Honors and Awards 9 Faculty Promotions 10 Grants Awarded 13 In Memoriam 15 New Administrative Staff 16 New Faculty 7 17 Research 18 COVID-related Research 20 Feature Article: Columbia Researchers United Build a COVID-19 Patient Biobank 27 Lab Snapshot: Impact of COVID-19 on Histology 28 New Residents & Fellows Columbia Pathology and Cell Biology Report Chairman Kevin A. Roth, MD, PhD Donald W. King, M.D. and Mary Elizabeth King, M.D. Professor of Pathology and Cell Biology Chair, Department of Pathology and Cell Biology Pathologist-in-Chief, CUIMC Department Administrator/CFO Joann Li, PA, MPH Editor and Layout Designer 20 Milan Fredricks Copy Editor and Webmaster Ping Feng Contributing Writers Alvaro Cuesta-Dominguez, Phd Annette Wu, MD Address correspondence to: PCB Reports, Editor c/o Milan Fredricks Columbia University Department of Pathology and Cell Biology 630 W. 168th St., Box 23 New York, NY 10032 E-mail: [email protected] Website: pathology.columbia.edu on the cover: Illustration, men and women wearing masks 24 (Source: graphics4u on envato elements) FROM THE CHAIR A Changing Landscape ARS -CoV-2 had, and world to advance studies of continues to have, a the virus and to develop novel Grants Awarded Sdevastating effect on our SARS-CoV-2 assays and therapies community. At its peak in mid- (https://www.pathology.columbia.
    [Show full text]
  • Development of a Quality Monitoring Program for Platelet Components: a Report of the first Four Years’ Experience At
    ORIGINAL ARTICLE Development of a quality monitoring program for platelet components: a report of the first four years’ experience at Canadian Blood Services_3402 1..9 Elena Levin, Craig Jenkins, Brankica Culibrk, Maria I.C. Gyöngyössy-Issa, Katherine Serrano, and Dana V. Devine ormal biologic differences among donors BACKGROUND: A quality monitoring program (QMP) mean that a degree of variation is inherent in for platelet concentrates (PCs) was implemented at blood components produced for transfusion.1 Canadian Blood Services (CBS) to improve standards Despite this, blood product providers strive to and to better understand platelet (PLT) products by Ngenerate components that are of high quality and are supplementing routine quality control (QC). optimally standardized to guarantee safety and effective- STUDY DESIGN AND METHODS: Annual surveys of ness.2,3 Quality control (QC) of components prepared from PCs from CBS production sites were conducted, with whole blood donations occurs at expiry and focuses on four completed to date (QMP Cycles 1-4) spanning two the product’s safety and compliance with regulatory stan- different PC production methods: PLT-rich plasma dards. For platelet concentrates (PCs), standards include (PRP) and buffy coat (BC). Randomly selected PCs pH, platelet (PLT) count per unit, sterility, and residual were sent to a central laboratory and tested 1 day after white blood cell count if the product is leukoreduced,4,5 all expiry. An expanded panel of tests including CD62P of which are monitored by routine QC at Canadian Blood expression by flow cytometry, mean PLT volume, PLT Services (CBS). Although production of blood compo- count and morphology, extent of shape change, and nents for transfusion purposes has increasingly adopted a PLT metabolic parameters, were applied.
    [Show full text]
  • Collaborative Study on the First WHO Repository of Red Blood Cell
    WHO/BS/2019.2377 ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 21 to 25 October 2019 Collaborative Study on the First WHO Repository of Red Blood Cell Transfusion-Relevant Bacterial Reference Strains Marcel Prax, Kay-Martin Hanschmann and Oleg Krut* and the Collaborative Study Group** *Division of Microbiology, Head Prof Isabelle Bekeredjian-Ding Paul-Ehrlich-Institut,Paul-Ehrlich-Straße 51-59, D-63225 Langen, Germany **ISBT WP Transfusion Transmitted Infectious Diseases Subgroup on Bacteria Chairs: Carl P McDonald and Sandra Ramirez-Arcos See Appendix 1 NOTE: This document has been prepared for the purpose of inviting comments and suggestions on the proposals contained therein, which will then be considered by the Expert Committee on Biological Standardization (ECBS). Comments MUST be received by 27 September 2019 and should be addressed to the World Health Organization, 1211 Geneva 27, Switzerland, attention: Technologies, Standards and Norms (TSN). Comments may also be submitted electronically to the Responsible Officer: Dr Ivana Knezevic at email: [email protected]. © World Health Organization 2019 All rights reserved. This draft is intended for a restricted audience only, i.e. the individuals and organizations having received this draft. The draft may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means outside these individuals and organizations (including the organizations' concerned staff and member organizations) without the permission of the World Health Organization. The draft should not be displayed on any website. Please send any request for permission to: Dr Ivana Knezevic, Technologies Standards and Norms, Department of Essential Medicines and Health Products, World Health Organization, CH-1211 Geneva 27, Switzerland.
    [Show full text]
  • ACBTSA Weighs What Is Tolerable Risk in the U.S. Blood Supply And
    2018 #31 September 14, 2018 INSIDE: ACBTSA Weighs What Is Tolerable Risk in the U.S. Blood Supply AABB, ABC, ARC Submit and How That May Inform Decision-making a Joint Perspective on Tolerable Risk in Blood The 49th Meeting of the U.S. Department of Health and Human Services (HHS) th Safety at 49 ACBTSA Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) took Meeting ........................ 3 place in Arlington, Va. on Thursday, September 13th., New Chair Jackie Fredrick, AABB Interorganizational Task Force on Domestic MBA, the former Versiti CEO, lead a one-day meeting to begin an exploration of Disaster and Acts of risk in the blood supply that will eventually result in recommendations to the As- Terrorism Urges sistant Secretary of Health and Human Services (ASH). The meeting focused on Americans to Donate risks from infection from a patient perspective including presentations from patient ahead of Hurricane Florence ....................... 4 advocacy groups and public comments. Its purpose was to inform the committee in Upcoming ABC Webinars advance of formulating specific recommendations to the ASH on how HHS should – Don’t Miss Out! .......... 4 consider a department-wide approach to decision making in this space. 2018 ABC Financial Ratio Survey .......................... 5 Jay Menitove, MD, the past chair of ACBTSA, presented updates from the Sustain- SMT Journal Club ability Workgroup, similar in content to that presented at the ABC Annual Meeting Recording Available ..... 5 in March 2018. He noted that BARDA analyses of the fiscal stability of the blood REGULATORY NEWS .... 6 community, including data from ABC centers, are in progress and should be avail- BRIEFLY NOTED ...........
    [Show full text]
  • 27Th Regional Congress of the ISBT
    27th Regional Congress of the ISBT June 17 - 21, 2017 Copenhagen, Denmark In conjunction with Final Programme The Organisation of Transfusion Centres in Denmark Tab_1 27th Regional Congress of the International Society of Blood Transfusion, Copenhagen, Denmark June 17 - 21, 2017 Tab_2 Tab_3 Tab_4 Tab_5 Acknowledgements Table of Contents Corporate Partners ISBT is pleased to acknowledge the following Corporate Partners Introduction: - Words of Welcome 5 - Future Congresses 7 GOLD - Committees 8 - Reviewers 10 - Congress Organisers 13 ISBT 14 ISBT Working Party & other Meetings 17 General Scientific Information 19 Congress General Information 21 Programme at a Glance 24 Scientific Programme 29 Speaker Index 84 Posters 89 Other Information 93 General Information 94 BRONZE: Social Programme 96 Floor Plans 100 Exhibition 2 3 Introduction Introduction Word of Welcome Congress President and Chairman of the Local Organizing Committee Dear Friends and Colleagues, We – the local organizing and scientific committees – are looking forward to seeing you at the 27th Regional Congress of the International Society of Blood Transfusion in Copenhagen, Denmark, June 17-21, 2017. With the help from multiple international reviewers and through a scientific meeting with the participation of recognized international experts the final educational and scientific programme with invited speakers, oral and poster presentations has been put together. We are happy that it seems to fulfill our aims for the congress so it will confront you with the frontiers of research and knowledge in transfusion medicine and related fields. We also hope to see you at Saturday’s local sessions to get the Scandinavian angle of our field. However, the success of the congress depends on you! We hope you will challenge the invited speakers and presenters with intriguing questions and comments to secure lively discussions.
    [Show full text]
  • Proceedings of the Food and Drug Administration Public Workshop on Pathogen Reduction Technologies for Blood Safety 2018
    CONFERENCE REPORT Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 Chintamani Atreya ,1 Simone Glynn,2 Michael Busch,3 Steve Kleinman,4 Edward Snyder,4 Sara Rutter,5 James AuBuchon,6 Willy Flegel,7 David Reeve,8 Dana Devine,9 Claudia Cohn ,9 Brian Custer,3 Raymond Goodrich,10 Richard J. Benjamin,11 Anna Razatos,12 Jose Cancelas,13 Stephen Wagner,8 Michelle Maclean,14 Monique Gelderman,15 Andrew Cap,16 and Paul Ness17 n November 29, 2018, experts in the field of mitigate these risks in the United States including the introduc- infectious diseases, pathogen reduction technol- tion of increasingly sensitive laboratory screening testing ogies (PRTs) and other participants from blood platforms and PRTs for PLTs and plasma products. In a first centers, academia, and industry gathered at the part, the session includes a general overview of the evolution OFood and Drug Administration (FDA) White Oak Campus in of responses to established, emerging, and reemerging Silver Spring, Maryland, for a 2-day public workshop entitled transfusion-transmitted infectious diseases in the past 50 years. “ ” Pathogen Reduction Technologies for Blood Safety. The Further, it addresses the need for ongoing surveillance for and workshop opened with welcome remarks from Dr. Nicole systematic responses to emerging infectious diseases (EIDs), fi Verdun, Director, Of ce of Blood Research and Review optimally with sensitive metagenomics, multiplexed nucleic (OBRR), Center for Biologics Evaluation and Research acid amplification technology (NAT) and serologic testing (CBER), FDA, followed by introductory remarks from strategies in sentinel global donor populations. This is followed Dr.
    [Show full text]
  • The Centre for Blood Research Presents…
    The Centre for Blood Research presents… Live Webcast: https://tinyurl.com/2017NBS-Webcast For registration information visit www.cbr.ubc.ca Each registered participant will be able to claim 6.5 MOC Section 1 credits by attending all sessions. 7:15 – 7:50 Registration and Breakfast 7:50 – 8:00 Dana Devine, PhD, UBC, Opening Remarks 8:00 – 8:35 Peter Newman, PhD, BloodCenter of Wisconsin, “CRISPR-mediated generation of antigeni- cally-distinct platelet progenitors from human iPS cells” 8:35 – 9:10 Heather Pidcoke, MD, PhD, Terumo BCT, “Refrigerated (4°C) Platelets: New Opportunities for Improving the Care of Bleeding Patients” 9:10 – 9:45 Shibani Pati, MD, PhD, Blood Systems Research Institute, “Regulation of Organ Injury in Trau- ma and Critical Care Medicine by Plasma and Platelet Transfusion” 9:45 – 10:25 Coffee break and posters 10:25 – 10:45 Selected Abstract Presentations - Andrew Wei-Yeh Shih, Emel Islamzada 10:45 – 10:55 Hugh Kim, DMD, PhD, FRCD(C), UBC, “Platelet signaling from an oral health perspective” 10:55 – 11:30 Mohandas Narla, DSc, New York Blood Centre, “Insights into Erythropoiesis and Red Cell Biol- ogy relevant to Transfusion Medicine” 11:30 – 12:05 James Piret, ScD, FCIC, UBC, “Raman Spectroscopy as a Process Analytical Technology for Cellular Therapy Applications” 12:05 – 12:35 “Shot-gun" talks 12:35 - 1:35 Buffet lunch and posters 1:35 – 2:10 Jean Wang, MD, PhD, FRCPC, Princess Margaret Cancer Centre, “A Social History of Transfu- sion Medicine” 2:10 – 2:25 Krista Klokeid, “Transfusion medicine through the eyes of
    [Show full text]
  • Pathogen Reduction Technologies for Blood Safety; Public Workshop Part 2
    UNITED STATES FOOD AND DRUG ADMINISTRATION PATHOGEN REDUCTION TECHNOLOGIES (PRT) FOR BLOOD SAFETY PUBLIC WORKSHOP Silver Spring, Maryland Thursday, November 29, 2018 2 1 PARTICIPANTS: 2 Welcome: 3 NICOLE VERDUN, M.D.. OBRR, CBER 4 Food and Drug Administration 5 Opening Remarks: 6 PETERS MARKS, M.D., Ph.D. CBER 7 Food and Drug Administration 8 SESSION 1: Blood-Borne Infectious Agents and Their Impact on Blood Safety: 9 SIMONE GLYNN, M.D., MPH, Moderator 10 NHLBI National Institutes of Health 11 Risks to Blood Safety From Infectious Agents: 12 MICHAEL BUSCH, M.D., Ph.D. 13 Vitalant Research Institute 14 Pathogen Reduction: An Overview of Policy Issues: 15 STEVE KLEINMAN, M.D. University of British Columbia 16 Pathogen Reduction Technologies for Platelets: 17 Current Status in the United States: 18 EDWARD SNYDER, M.D., FACP Yale University, Yale New Haven Hospital 19 PRT for Plasma in the United States: 20 JAMES AUBUCHON, M.D., FACAP, FRCP (Edin) 21 Bloodworks Northwest, University of Washington 22 3 1 PARTICIPANTS (CONT'D): 2 Panel Discussion: 3 MICHAEL BUSCH, M.D., Ph.D. Vitalant Research Institute 4 STEVE KLEINMAN, M.D. 5 University of British Columbia 6 EDWARD SNYDER, M.D., FACP Yale University, Yale New Haven Hospital 7 JAMES AUBUCHON, M.D., FACAP, FRCP (Edin) 8 Bloodworks Northwest, University of Washington 9 SESSION 2: Implementation of Pathogen Reduction Technology for Blood Products in the U.S.: 10 BILL FLEGEL, M.D., Moderator 11 NIH Clinical Center 12 Experience Implementing PRT: 13 DAVID REEVE, MBA, MHA American Red Cross 14 PRT Implementation in a Hospital-Based Blood 15 Center & Acceptance by Hospital Staff: 16 BILL FLEGEL, M.D., Moderator NIH Clinical Center 17 Impact of PRT on Platelet Quality, Count, and 18 Clinical Implications: 19 DANA DEVINE, Ph.D.
    [Show full text]